The ‘Global Lung Cancer Therapeutics Market Share, Report and Forecast 2023-2028’ by Expert Market Research gives an extensive outlook of the global lung cancer therapeutics market, assessing the market on the basis of its segments like cancer types, therapies, end uses, distribution channels, and major regions.
The report studies the latest updates in the market, along with their impact across the market. It also analysis the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.
Lung Cancer Therapeutics Market Size, Share, Price Trends, Industry Report, Key Players, Major Segments, and Forecast
The key highlights of the report include:
Market Overview (2018-2028)
- Forecast CAGR (2023-2028): 10.10%
|Growth Rate CAGR||10.10%|
|Major Players||Genentech, Inc., AstraZeneca PLC, Novartis AG., Merck KGaA,
F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH and among others.
The lung cancer therapeutics market is being driven by an increase in lung cancer diagnoses as a result of improved cancer awareness in both developed and developing economies, as well as the introduction of new medical diagnostic tools and improved therapies. The introduction of expensive medications, novel radiation therapy, and an increase in the prevalence of non-small cell lung cancer (NSCLC) are the main drivers propelling the growth of the lung cancer therapeutics market.
Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/lung-cancer-therapeutics-market/requestsample
The market is further fuelled due to the increased spending on research and innovation by major players. The advent of nanomedicine to treat lung cancer and the rising number of approvals in the lung cancer treatments market is also aiding the market growth. The lung cancer therapeutics industry is anticipated to grow along with increased regulatory approvals.
Rising prevalence of lung diseases including lung cancer in developing nations like China and India are propelling the market for lung cancer therapeutics. However, the market for lung cancer therapeutics is being constrained by the rising costs and limited accessibility of specialised medications and advanced immunotherapies in nations with weaker healthcare infrastructure. The widespread use of traditional primary medications may limit the demand for advanced lung cancer treatments in the Asia Pacific.
Lung Cancer Therapeutics Industry Definition and Major Segments
Lung cancer is a cancer that develops in lung tissues, typically in the cells lining air passageways. Surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments can be used to treat lung cancer. Smoking is one of the main causes of lung cancer. Inhaling second-hand smoke, using other tobacco products, or genetic factors can also contribute to it.
Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/lung-cancer-therapeutics-market
Based on cancer type, the market is categorised into:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer (SCLC)
On the basis of therapy, the market is segmented into:
- Radiation Therapy
- Targeted Therapy
Based on end use, the market is divided into:
- Speciality Clinics
On the basis of distribution channels, the market is categorised into:
- Hospital Pharmacy
- Retail Pharmacy
Based on region, the market is segmented into:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Lung Cancer Therapeutics Market Trends
A key trend in the lung cancer therapeutics market is the use of machine learning in combination with cancer treatment for high precision treatment and better tracking. The creation and application of nanomedicine may present fresh prospects for market participants and enhance the market’s growth. This form of treatment will limit the negative effects of medications and target the specific cancer cells for treatment.
Increase in pollution worldwide, particularly in urban areas and regions with high vehicular traffic, is further increasing the prevalence of lung cancer, bolstering the demand for the lung cancer therapeutics market. Repeated exposure to high levels of air pollution have been linked with increased incidences of lung cancer in the long-term. Based on current levels of air pollution, cases of lung cancer are likely to surge in the coming years.
Due to the rising number of cases in hospitals, hospital pharmacies are anticipated to hold a significant position among the various distribution channels. Since customers are increasingly choosing to get their medications from neighbouring stores, retail pharmacies are also expanding in the market. A higher growth rate is anticipated for online pharmacies as a result of the e-commerce sector’s rapid expansion.
The lung cancer therapeutics market share is increasing in North America due to the development of innovative treatment methods such targeted medication therapy, high numbers of smokers, and increased awareness regarding early testing. The United States is a sizable market for NSCLC due to the high incidence rate increase in the ageing population.
Key Market Players
The major players in the global lung cancer therapeutics market report are Genentech, Inc., AstraZeneca PLC, Novartis AG, Merck KGaA, F. Hoffmann-La Roche Ltd, and Boehringer Ingelheim International GmbH, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: Ian Bell, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA